Round includes participation from Medtronic and top healthcare investorsThe raise, which drew substantial investor interest, was co-led by Medtronic, TechWald Next S.p.A., and S3 Ventures. SBI Investment Company Ltd. and Florida Opportunity Fund also joined previous investors Santé Ventures, Syntheon, Hatteras Venture Partners, and Epidarex Capital to complete the syndicate. The financing will support completion of the company’s ongoing Investigational Device Exemption study entitled Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions (TURBO), and further expansion of its patented and proprietary technology platform which includes a full line of catheter sizes.
“This financing enables us to complete the TURBO study, expand clinical experience across leading stroke centers, and data permitting, seek FDA approval for the RapidPulse system,” said Sean McBrayer, Chief Executive Officer of RapidPulse. “We are particularly encouraged by the support of both leading financial investors and one of the largest medical technology companies in the world, Medtronic, reflecting growing recognition of the potential impact of our approach to stroke treatment.”
Alessandro Piga, CEO of TechWald Next S.p.A., commented, “We evaluated a broad range of emerging stroke technologies and believe RapidPulse represents one of the most compelling innovation opportunities in the field. The company combines differentiated technology, strong intellectual property, and an experienced leadership team. We are excited to support RapidPulse as it advances through this next stage of clinical development. RapidPulse represents particularly well the highly innovative therapies that TechWald is committed to foster in Cardiovascular and Neurovascular diseases.”
“RapidPulse is exactly the kind of company S3 Ventures was built to back — a highly differentiated technology, a rigorous clinical strategy, and a team that has earned the confidence of both leading financial investors and a major strategic partner. Stroke remains one of the most acute unmet needs in medicine, and we believe RapidPulse’s pulsed aspiration approach has real potential to meaningfully improve outcomes for patients. We are proud to co-lead this round and to support the team as they advance through their pivotal trial and toward FDA approval,” said Brian R. Smith, Founder and Managing Director, S3 Ventures.
RapidPulse is developing a proprietary aspiration technology designed to enhance clot engagement and removal through a controlled cyclic aspiration approach. The system is currently being evaluated in the United States and Europe as part of the TURBO study to support the company’s US regulatory pathway. With strong clinical momentum and new growth capital in place, RapidPulse is positioned to continue advancing its clinical program and technology development in collaboration with leading stroke centers.
ABOUT RAPIDPULSE
RapidPulse, Inc. is a medical technology company dedicated to advancing the treatment of acute ischemic stroke through innovative aspiration technologies. The company’s proprietary platform is designed to improve clot removal efficiency and procedural consistency for physicians performing mechanical thrombectomy.
The company, spun out of Syntheon and headquartered in Miami, Florida is conducting clinical studies in the United States and Europe and continues to advance its technology toward regulatory milestones.
